Latest Conference Articles

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.

There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Inhalation therapy is reliant upon correct inhaler technique to allow for optimal deposition of medication.

The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.

As the number of patients hospitalized with COVID-19 has surged, hospitals have been faced with the challenge of converting various spaces into ICUs and COVID-19 units.

The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

According to investigators, most medications should be stored at room temperature, between 68 and 77 degrees Fahrenheit.

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.

Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.

The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.

Session at at the San Antonio Breast Cancer Symposium featured several abstract presentations on disparities in health care access in breast cancer, including research on the necessity of avoiding a one-size-fits-all approach to medicine.

The COVID-19 Pandemic has compounded the opioid crisis.

Until COVID-19 vaccines are widely available, Anthony Fauci, MD, said the importance of public health measures cannot be understated.

Specifically, in rural settings, growing primary care provider shortages impact patient access to care.

Overdiagnosis of breast cancer can lead to unnecessarily aggressive treatments and mastectomies.

In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.

Grief can affect an organization as well as an individual; however, there are management strategies that can be used for addressing these issues.

There were significant modifications in breast cancer treatment due to the coronavirus disease 2019 pandemic, such as high rates of NET chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

National Academy of Medicine President Victor J. Dzau, MD was among those honored at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Tesetaxel is a novel, oral taxane with several unique properties being investigated for use in patients with HER2-negative, HR-positive metastatic breast cancer.

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII (FVIII), and the disorder is understudied given its rarity and the lack of randomized prospective trials to guide therapy.

Pharmacists can provide a multitude of billing opportunities for their health systems and bringing these opportunities to executives is essential during a time of budget tightening.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.